Navigation Links
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Date:6/6/2009

SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced positive secondary findings from the first of four Phase 3 trials of its lead investigational product Contrave(R) (naltrexone sustained release (SR)/bupropion SR). These data were presented in one oral and two poster presentations at the American Diabetes Association's (ADA) 69th Scientific Sessions in New Orleans, Louisiana.

The oral presentation highlighted the significant improvements in eating control experienced by patients treated with Contrave versus placebo (p< 0.01), as well as previously reported results on the primary weight loss endpoints and measures of cardiometabolic risk. "NB-302 results show that Contrave initiates and sustains weight loss and can improve predictive markers for heart disease such as waist circumference, triglycerides, HDL-cholesterol and hsCRP," said Eduardo Dunayevich, Chief Medical Officer, Orexigen Therapeutics. "Furthermore, due to its unique effects on brain reward centers, Contrave may allow patients to better control their eating habits, potentially providing an important advantage to millions of Americans who struggle with obesity."

The mood and weight-related quality of life findings observed in the Contrave group were discussed in the oral presentation and reviewed in greater detail in the poster presentations. Contrave was not associated with suicidality or worsening of mood or depressive symptoms, and in fact was associated with a decreased incidence of treatment-emergent depression compared to placebo. In addition, Contrave patients achieved significant improvements in overall quality of life (p< 0.01) and reported that benefits, such as improved physical function and self-esteem, occurred early in
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
2. Orexigen(R) Therapeutics to Present at Upcoming Meetings
3. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
4. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
5. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
6. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
7. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Corporation,s (Amex: ETC ) ("ETC" or the ... contract with the Netherlands,Institute for Safety, NIFV, to ... Simulator for Aircraft Rescue Fire Fighting., The ... military helicopter,scenario consisting of AH-64 Apache helicopters parked ...
... FRANCISCO, Calif., Nov. 3 Portola,Pharmaceuticals, a ... advances in cardiovascular and inflammatory,diseases, and cancer, ... enrollment,in a large Phase II clinical trial ... inhibitor anticoagulant, for stroke prevention in patients ...
... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... matrix, today announced it has started,a Phase ... enzyme,(rHuPH20) co-formulations with Humulin(R) R (regular insulin ... Type 1 diabetic,patients. This study is designed ...
Cached Biology Technology:Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 2Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 2Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 4Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 2Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 3Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 4
(Date:8/29/2014)... stretch them, twist them, fold them: modern materials that ... potential, whether as artificial skin or electronic paper. , ... a challenge but a new way of working with ... a game-changer. , Previous success in the field ... use of precious gold and silver nanowires. , ...
(Date:8/28/2014)... pleased to announce the selection of Dr. Fred Baxendale ... acknowledges those who have served ESA for at least ... the Society that has reached an extraordinary level. Candidates ... Board and then voted on by the ESA membership. ... at Entomology 2014, ESA,s Annual Meeting in Portland, Oregon ...
(Date:8/28/2014)... news release is available in German . ... water fish, owes its name to a striking pattern of ... types, black cells, reflective silvery cells, and yellow cells emerge ... and arrange as a multilayered mosaic to compose the characteristic ... three cell types have to interact to form proper stripes, ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Fred Baxendale selected as Honorary Member of the Entomological Society of America 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... in German . , Researchers at the Max ... the Czech Academy of Sciences in Prague have developed a new ... acids, amino acids and other organic substances from plant or animal ... liter -- is sufficient to identify certain blood related metabolites. ...
... of fishing gear could help the world,s coral reefs and their ... team of scientists led by Dr Josh Cinner of the ARC ... has proposed that bans on fishing gear - like spear guns, ... in the recovery of reefs and fish populations hard hit by ...
... Although worlds apart, the way fish learn could be ... a new research study. A common species of fish ... nine-spined stickleback, could be the first animal shown to exhibit ... compare the behaviour of other sticklebacks with their own experience ...
Cached Biology News:An easy way to find a needle in a haystack by removing the haystack 2An easy way to find a needle in a haystack by removing the haystack 3Gear bans 'can help save reefs' 2Gear bans 'can help save reefs' 3Common fish species has 'human' ability to learn 2Common fish species has 'human' ability to learn 3
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Request Info...
MOUSE ANTI HUMAN FACTOR I...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Biology Products: